Innovation  Saving  Lives

The Latest from OBD

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.

Jakub, JW., et. al.,
Melanoma Research

FC-g Receptor Targeting Reduces Bone Disease in a Pre-clinical Model of Multiple Myeloma

Williams, et. al.,
American Society of Haematology

Chromatin barcodes as biomarkers for melanoma.

Bastonini, E., et. al.,
Pigment Cell Melanoma Research

A blood-based epigenetic test for early detection of hepatocellular carcinoma (HCC).

Lim, EH., et. al.,
J Clinical Oncology

Chromatin signatures of DLBCL subtypes.

Field, et. al.,
Cancer Research

Current Advances in Epigenetics.

Hunter, et., al.,
Clinical and Statistical Consideration in Personalized Medicine

Formation of distinct chromatin conformation signatures epigenetically regulate macrophage activation.

Mukhopadhyay, et. al.,
International Immunopharmacology

Validation of a new Epigenetic-based Prognostic Blood test to predict Prostate Cancer Aggressiveness

Pchejetski, D, et. al.,
Annals of Oncology

Development of novel ALS treatment on the basis of mechanisms of cellular chronological life span control.

Youdell, M.,,
12th Annual Northeast Amyotrophic Lateral Sclerosis Consortium

A blood-based epigenetic test for early detection of nasopharyngeal carcinoma (NPC).

Tan, Y., et. al.,
J Clinical Oncology